Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
BACKGROUND
Prostate-specific antigen (PSA) is the single most important tumor marker in early detection and monitoring of prostate cancer (CaP). However, routine analysis of serum PSA concentrations does not allow differentiation between CaP and prostatic diseases. The aim of the present study was to evaluate the usefulness of the serum-to-urinary PSA ratio in a clinical setting.


METHODS
In a retrospective clinical study, we determined serum and urine PSA concentrations in 48 patients with benign prostatic hyperplasia (BPH) and 57 patients with histologically confirmed CaP.


RESULTS
The serum-to-urinary PSA ratio is able to discriminate BPH from CaP.


CONCLUSIONS
Determination of the serum-to-urinary PSA ratio enhances the specificity of PSA in screening for CaP and monitoring of patients with CaP under androgen deprivation therapy.
Hillenbrand
M
M
Department of Urology, Faculty of Medicine, University of Rostock, Ernst-Heydemann-Str. 6, D-18057 Rostock, Germany.
Bastian
M
M
Steiner
M
M
Zingler
C
C
Müller
M
M
Wolff
J M
JM
Seiter
H
H
Schuff-Werner
P
P
D000368:Aged; D006801:Humans; D008297:Male; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000652:urine; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000175:diagnosis / Q000652:urine; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000652:urine
D017430:Prostate-Specific Antigen